These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1171496)

  • 21. Neuropharmacological profile of MD 790501, a new benzamide derivative.
    Jalfre M; Bucher B; Dorme N; Mocquet G; Porsolt RD
    Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):232-56. PubMed ID: 6139097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for evaluation of long acting neuroleptic drugs in animals.
    Kazdová E; Dlabac A; Metysová J
    Act Nerv Super (Praha); 1972; 14(2):126-7. PubMed ID: 5064759
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacological studies on triazine derivatives V Sedative and neuroleptic actions of 2-amino-4-[4-(2-hydroxyethyl)-piperazin-1-yl]-6-trifluoromethyl-s-triazine (TR-10).
    Tobe A; Kobayashi T
    Jpn J Pharmacol; 1976 Oct; 26(5):559-70. PubMed ID: 12393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
    Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
    Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
    Janssen PA; Niemegeers CJ; Schellekens KH; Dresse A; Lenaerts FM; Pinchard A; Schaper WK; van Nueten JM; Verbruggen FJ
    Arzneimittelforschung; 1968 Mar; 18(3):261-79. PubMed ID: 4386815
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacological properties of a new potential neuroleptic drug oxyprothepin. IV. Antiadrenergic action and influence on brain monoamines.
    Dlabac A; Metys J; Metysová J
    Act Nerv Super (Praha); 1971; 13(3):188-9. PubMed ID: 5113833
    [No Abstract]   [Full Text] [Related]  

  • 27. Is dopamine antagonism a requisite of neuroleptic activity?
    Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide.
    Yamada K; Furukawa T
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):76-85. PubMed ID: 7194019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Behavioral pharmacology of mianserin hydrochloride, a new antidepressant (author's transl)].
    Kamioka T; Sakai Y
    Nihon Yakurigaku Zasshi; 1980 Sep; 76(6):533-47. PubMed ID: 7193623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological effects of Ro 22-1319: a new antipsychotic agent.
    Davidson AB; Boff E; MacNeil DA; Wenger J; Cook L
    Psychopharmacology (Berl); 1983; 79(1):32-9. PubMed ID: 6132425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1974 Jun; 27(1):46-58. PubMed ID: 4604756
    [No Abstract]   [Full Text] [Related]  

  • 32. The nucleus amygdaloideus centralis and neuroleptic activity in the rat.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1974 Feb; 25(2):138-46. PubMed ID: 4154850
    [No Abstract]   [Full Text] [Related]  

  • 33. The action of neuroleptics in rats with altered catecholamine metabolism. I. The influence of MAO inhibitors on the behavioral actions of chlorpromazine, haloperidol, and thioridazine.
    Vetulani J
    Pol J Pharmacol Pharm; 1973; 25(1):41-52. PubMed ID: 4798098
    [No Abstract]   [Full Text] [Related]  

  • 34. Psychopharmacological studies on (--)-nuciferine and its Hofmann degradation product atherosperminine.
    Bhattacharya SK; Bose R; Ghosh P; Tripathi VJ; Ray AB; Dasgupta B
    Psychopharmacology (Berl); 1978 Sep; 59(1):29-33. PubMed ID: 100809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The activity of some neuroleptic drugs and amphetamine in normal and isolated rats.
    Kostowski W; Czlonkowski A
    Pharmacology; 1973; 10(2):82-7. PubMed ID: 4797045
    [No Abstract]   [Full Text] [Related]  

  • 36. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The central nervous system pharmacology of an anti-emetic dihydroindolone derivative.
    Holmes SW; Gylys JA
    Arzneimittelforschung; 1973 Sep; 23(9):1314-8. PubMed ID: 4204318
    [No Abstract]   [Full Text] [Related]  

  • 38. BRL 20596, a novel anilide with central dopamine antagonist activity.
    Campbell W; Clark MS; Mitchell PJ; Needham PL; Semple JM
    Psychopharmacology (Berl); 1986; 89(2):208-15. PubMed ID: 3088638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and pharmacological study of the thiophene analogue of taclamine, QM-7184, a new neuroleptic drug with potent alpha-adrenoceptor blocking activity.
    Arribas E; Vega S; Benito C; Fernandez-Tome MP; del Rio J
    Arzneimittelforschung; 1983; 33(10):1417-21. PubMed ID: 6140017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
    Yamamoto T; Ueki S
    J Pharmacobiodyn; 1989 Nov; 12(11):681-92. PubMed ID: 2632765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.